- Home
- PLRX vs ORIC Comparison
PLRX vs ORIC Comparison
Compare PLRX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- ORIC
- Stock Information
- Founded
- PLRX 2015
- ORIC 2014
- Country
- PLRX United States
- ORIC United States
- Employees
- PLRX N/A
- ORIC N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- ORIC Health Care
- Exchange
- PLRX Nasdaq
- ORIC Nasdaq
- Market Cap
- PLRX 682.2M
- ORIC 633.7M
- IPO Year
- PLRX 2020
- ORIC 2020
- Fundamental
- Price
- PLRX $11.17
- ORIC $10.12
- Analyst Decision
- PLRX Strong Buy
- ORIC Strong Buy
- Analyst Count
- PLRX 7
- ORIC 9
- Target Price
- PLRX $40.50
- ORIC $18.75
- AVG Volume (30 Days)
- PLRX 577.5K
- ORIC 597.6K
- Earning Date
- PLRX 02-26-2025
- ORIC 03-10-2025
- Dividend Yield
- PLRX N/A
- ORIC N/A
- EPS Growth
- PLRX N/A
- ORIC N/A
- EPS
- PLRX N/A
- ORIC N/A
- Revenue
- PLRX N/A
- ORIC N/A
- Revenue This Year
- PLRX N/A
- ORIC N/A
- Revenue Next Year
- PLRX N/A
- ORIC N/A
- P/E Ratio
- PLRX N/A
- ORIC N/A
- Revenue Growth
- PLRX N/A
- ORIC N/A
- 52 Week Low
- PLRX $10.22
- ORIC $6.33
- 52 Week High
- PLRX $18.92
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- PLRX 37.86
- ORIC 54.53
- Support Level
- PLRX $10.94
- ORIC $7.86
- Resistance Level
- PLRX $12.70
- ORIC $11.15
- Average True Range (ATR)
- PLRX 0.77
- ORIC 0.72
- MACD
- PLRX -0.17
- ORIC 0.19
- Stochastic Oscillator
- PLRX 12.27
- ORIC 51.37
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.